SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Katsetos, C. D.
Right arrow Articles by Mörk, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katsetos, C. D.
Right arrow Articles by Mörk, S. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Class III ß-Tubulin Isotype: A Key Cytoskeletal Protein at the Crossroads of Developmental Neurobiology and Tumor Neuropathology

Christos D. Katsetos, MD, PhD, MRCPath

Department of Pediatrics, Drexel University College of Medicine Section of Neurology, christos.d.katsetos{at}drexel.edu, Department of Pathology and Laboratory Medicine St. Christopher's Hospital for Children, Philadelphia, PA, christos.d.katsetos{at}drexel.edu

Agustin Legido, MD, PhD

Department of Pediatrics Drexel University College of Medicine

Elias Perentes, MD, DMSc

Preclinical Safety Novartis Pharma AG, Basel, Switzerland

Sverre J. Mörk, MD, PhD

Department of Pathology The Gade Institute, University of Bergen, Haukeland Hospital, Bergen, Norway

The expression of the cytoskeletal protein class III ß-tubulin isotype is reviewed in the context of human central nervous system development and neoplasia. Compared to systemic organs and tissues, class III ß-tubulin is abundant in the brain, where it is prominently expressed during fetal and postnatal development. As exemplified in cerebellar neurogenesis, the distribution of class III ß-tubulin is neuron associated, exhibiting different temporospatial gradients in the neuronal progeny of the external granule layer versus the neuroepithelial germinal matrix of the velum medullare. However, transient expression of this protein is also present in the telencephalic subventricular zones comprising putative neuronal and/or glial precursor cells. This temporospatially restricted, potentially non-neuronal expression of class III ß-tubulin may have implications in the accurate identification of presumptive neurons derived from transplanted embryonic stem cells. In the adult central nervous system, the distribution of class III ß-tubulin is almost exclusively neuron specific. Altered patterns of expression are noted in brain tumors. In "embryonal"-type neuronal/neuroblastic tumors of the central nervous system, such as the medulloblastomas, class III ß-tubulin expression is associated with neuronal differentiation and decreased cell proliferation. In contrast, the expression of class III ß-tubulin in gliomas is associated with an ascending grade of histologic malignancy and with correspondingly high proliferative indices. Thus, class III ß-tubulin expression in neuronal or neuroblastic tumors is differentiation dependent, whereas in glial tumors, it is aberrant and/or represents "dedifferentiation" associated with the acquisition of glial progenitor-like phenotype(s). From a diagnostic perspective, the detection of class III ß-tubulin immunostaining in neoplastic cells should not be construed as categorical evidence of divergent neuronal differentiation in tumors, which are otherwise phenotypically glial. Because class III ß-tubulin is present in neoplastic but not in normal differentiated glial cells, the elucidation of molecular mechanisms responsible for the altered expression of this isotype may provide critical insights into the dynamics of the microtubule cytoskeleton in the growth and progression of gliomas. (J Child Neurol 2003;18:851-866).

Journal of Child Neurology, Vol. 18, No. 12, 851-866 (2003)
DOI: 10.1177/088307380301801205


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
C. Dumontet, M. A. Jordan, and F. F.Y. Lee
Ixabepilone: targeting {beta}III-tubulin expression in taxane-resistant malignancies
Mol. Cancer Ther., January 1, 2009; 8(1): 17 - 25.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
E.-M. Jouhilahti, S. Peltonen, and J. Peltonen
Class III {beta}-Tubulin Is a Component of the Mitotic Spindle in Multiple Cell Types
J. Histochem. Cytochem., December 1, 2008; 56(12): 1113 - 1119.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
C. Q. Yu and M. I. Rosenblatt
Transgenic Corneal Neurofluorescence in Mice: A New Model for In Vivo Investigation of Nerve Structure and Regeneration
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1535 - 1542.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q. Shu, B. Antalffy, J. M. F. Su, A. Adesina, C.-N. Ou, T. Pietsch, S. M. Blaney, C. C. Lau, and X.-N. Li
Valproic Acid Prolongs Survival Time of Severe Combined Immunodeficient Mice Bearing Intracerebellar Orthotopic Medulloblastoma Xenografts
Clin. Cancer Res., August 1, 2006; 12(15): 4687 - 4694.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. Seve, J. Mackey, S. Isaac, O. Tredan, P.-J. Souquet, M. Perol, R. Lai, A. Voloch, and C. Dumontet
Class III {beta}-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
Mol. Cancer Ther., December 1, 2005; 4(12): 2001 - 2007.
[Abstract] [Full Text] [PDF]



Advertisement